The company manufactures various yeast products and derivatives used in the food, distillery, pharmaceutical, and animal feed industries.
The business lacks a durable moat as evidenced by low average net margins of 2.5% and an interest coverage ratio below 1.0, indicating a lack of pricing power against volatile raw material costs like molasses. While they have established brands like SUNRISE, the commodity nature of the product and low returns on capital suggest no significant structural advantage.
Capital has been primarily directed toward maintaining and expanding manufacturing facilities, including a new facility for yeast-based protein. However, historical returns on equity are poor at 5%, and the company has suspended dividends to preserve cash for expansion despite weak incremental returns on invested capital.
The company succumbed to a liquidity trap as the interest coverage ratio, already a dismal 0.25, failed to recover while debt-funded expansions yielded returns below the cost of capital. The massive pending tax litigation of 1,438.92 lakhs eventually resulted in an adverse judgment, wiping out the thin equity base. Stagnant revenue growth and negative EPS momentum, combined with the auditor-noted discrepancies in bank filings, led to a total loss of credit access, forcing a fire sale of commodity assets in a high-interest environment.
RichFakir rates Kothari Fermentation & Biochem Ltd's business quality as poor — 23/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
RichFakir's educational verdict on Kothari Fermentation & Biochem Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
View the full live analysis →